{"product_id":"azin2-antibody-antizyme-inhibitor-2-bha17105804","title":"AZIN2 Antibody \/ Antizyme inhibitor 2","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\u003cp\u003eAZIN2 Antibody \/ Antizyme inhibitor 2 is a research-use-only Rabbit polyclonal (rabbit origin) Rabbit IgG directed against \u003cstrong\u003eAZIN2 \/ Antizyme inhibitor 2\u003c\/strong\u003e. It is supplied for interpretation-focused detection and comparative profiling in WB, IHC. Reported localization context: Predominantly nuclear, possible cytoplasmic staining.\u003c\/p\u003e\n\u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eTarget context:\u003c\/strong\u003e This antibody is raised against \u003cem\u003eAmino acids C111-Q301 from the human protein were used as the immunogen for the AZIN2 antibody.\u003c\/em\u003e. Epitope context matters because isoforms, processing, and post-translational modifications can change what is accessible in a given assay.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormat:\u003c\/strong\u003e Antigen affinity purified. Format influences background and compatibility with different detection chemistries; conjugated formats (when present) can simplify multiplexing and reduce reliance on secondary reagents.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSpecies reactivity:\u003c\/strong\u003e Human, Mouse, Rat. Cross-species performance can vary with sequence divergence and epitope conservation, so interpretation should be anchored with appropriate biological controls.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLocalization:\u003c\/strong\u003e Predominantly nuclear, possible cytoplasmic staining. Subcellular compartment context can help guide expectations in imaging assays and informs fractionation-based comparisons in lysate workflows.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eApplications:\u003c\/strong\u003e WB, IHC. These indicate assay contexts where the antibody is commonly applied; actual performance depends on sample type and processing.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003ePolyclonal reagents can differ in how they recognize epitope features. Monoclonal antibodies often provide more consistent epitope targeting across lots, while polyclonal preparations may broaden recognition across related epitope variants. \u003c\/p\u003e\n\u003ch2\u003eBiological background\u003c\/h2\u003e\u003cp\u003e\u003cstrong\u003eAZIN2 \/ Antizyme inhibitor 2\u003c\/strong\u003e refers to the gene\/protein target stated in the product record. Protein targets can exhibit context-dependent expression, regulated turnover, isoform diversity, and post-translational modifications that affect apparent molecular weight and epitope accessibility. For curated functional annotation, sequence features, and expression context, consult \u003ca href=\"https:\/\/www.uniprot.org\/uniprotkb\/Q96A70\/entry\"\u003eUniProtKB Q96A70\u003c\/a\u003e, \u003ca href=\"https:\/\/www.ensembl.org\/\"\u003eEnsembl\u003c\/a\u003e, and \u003ca href=\"https:\/\/www.proteinatlas.org\/\"\u003eHuman Protein Atlas\u003c\/a\u003e.\u003c\/p\u003e\n\u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eIntegrating antibody-based detection with single-cell and spatial atlasing efforts to connect RNA programs with protein-level abundance and localization in defined cell states.\u003c\/li\u003e\n\u003cli\u003eExpanding multiplexed imaging and high-content screening, where reagent specificity, cross-reactivity risk, and channel design (including direct conjugates) become central to interpretation.\u003c\/li\u003e\n\u003cli\u003eGrowing emphasis on reproducibility and application-specific validation frameworks (e.g., genetic perturbation controls, orthogonal measurements, and independent antibody strategies) when drawing mechanistic conclusions.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon research applications\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eWestern blot (WB):\u003c\/strong\u003e commonly used to compare relative abundance\/size (e.g., band intensity or mobility shifts) between conditions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eImmunohistochemistry (IHC):\u003c\/strong\u003e commonly used to compare tissue- and cell-type–specific expression patterns in situ.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eInterpretation typically focuses on relative differences (presence\/absence, fold-changes, compartment shifts, or population-level shifts) rather than absolute quantitation. When signal changes are observed, they may reflect altered expression, altered localization\/trafficking, changes in modification state, or differences in sample composition; orthogonal readouts and appropriate controls help distinguish these possibilities.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eApplication details (record-specific):\u003c\/strong\u003e Western blot: 0.5-1ug\/ml,IHC (FFPE): 1-2ug\/ml\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eApplication notes (record-specific):\u003c\/strong\u003e Differences in protocols and secondary\/substrate sensitivity may require the AZIN2 antibody to be titrated for optimal performance.\u003c\/p\u003e\n\u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eProduct description (record-specific):\u003c\/strong\u003e Antizyme inhibitor 2 (AzI2), also known as arginine decarboxylase (ADC), is an enzyme that in humans is encoded by the AZIN2 gene. The protein encoded by this gene belongs to the antizyme inhibitor family, which plays a role in cell growth and proliferation by maintaining polyamine homeostasis within the cell. Antizyme inhibitors are homologs of ornithine decarboxylase (ODC, the key enzyme in polyamine biosynthesis) that have lost the ability to decarboxylase ornithine; however, retain the ability to bind to antizymes. Antizymes negatively regulate intracellular polyamine levels by binding to ODC and targeting it for degradation, as well as by inhibiting polyamine uptake. Antizyme inhibitors function as positive regulators of polyamine levels by sequestering antizymes and neutralizing their effect. This gene encodes antizyme inhibitor 2, the second member of this gene family. Like AZIN1, AZIN2 interacts with all three antizymes and stimulates ODC activity and polyamine uptake. However, unlike AZIN1, which is ubiquitously expressed and localized in the nucleus and cytoplasm, AZIN2 is predominantly expressed in the brain and testis and localized in the endoplasmic reticulum-golgi intermediate compartment. Recent studies indicate that AZIN2 is also expressed in specific cell types in ovaries, adrenal glands and pancreas, and in mast cells. The exact function of this gene is not known, however, available data suggest its role in cell growth, spermiogenesis, vesicular trafficking and secretion.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePotential confounders:\u003c\/strong\u003e isoforms, proteolytic processing, and PTMs can change epitope presentation and apparent size; fixation\/denaturation state can also expose or mask epitopes. Species differences near the epitope may affect cross-reactivity.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eControl concepts:\u003c\/strong\u003e include genetic perturbation (KO\/KD) or overexpression comparisons, orthogonal measurement (e.g., transcript or proteomics), and independent antibody\/epitope strategies. For conjugated reagents, include staining-only\/background controls appropriate to the detection chemistry.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eImmunogen\/epitope context is described as: \u003cem\u003eAmino acids C111-Q301 from the human protein were used as the immunogen for the AZIN2 antibody.\u003c\/em\u003e. Monoclonal and polyclonal formats differ in epitope breadth; this can influence sensitivity to sequence variants, isoforms, or PTM-dependent recognition.\u003c\/p\u003e\n\u003c!-- Sources (internal):\n- UniProtKB entry Q96A70 (UniProt Consortium): https:\/\/www.uniprot.org\/uniprotkb\/Q96A70\/entry\n- Ensembl genome browser (EMBL-EBI \/ Wellcome Sanger): https:\/\/www.ensembl.org\/\n- The Human Protein Atlas (KTH \/ SciLifeLab): https:\/\/www.proteinatlas.org\/\n- A proposal for validation of antibodies (Uhlén et al., Nature Methods, 2016): https:\/\/www.nature.com\/articles\/nmeth.3995.pdf\n- Getting to reproducible antibodies: the rationale for sequenced recombinant characterized reagents (Bradbury \u0026 Plückthun, PEDS, 2015): https:\/\/academic.oup.com\/peds\/article\/28\/10\/303\/1478378\n- Standardize antibodies used in research (Bradbury, Plückthun et al., Nature, 2015): https:\/\/www.nature.com\/articles\/518027a.pdf\n--\u003e","brand":"NSJ Bioreagents","offers":[{"title":"0.5mg\/ml if reconstituted with 0.2ml sterile DI water \/ 100 ug","offer_id":53210323583341,"sku":"R32486","price":462.47,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/get_image_5f00c43a-e2e1-4d17-b052-df3e0afc200b.jpg?v=1775785754","url":"https:\/\/www.ebiohippo.com\/products\/azin2-antibody-antizyme-inhibitor-2-bha17105804","provider":"BioHippo","version":"1.0","type":"link"}